Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yongxin Han

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Journal of Medicinal Chemistry|June 26, 2024
Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRAS<sup>G12C</sup> InhibitorXiaoshen Ma, David L Sloman, Ruchia Duggal, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Novel Quinoline-Based P2-P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease InhibitorsUnmesh Shah, Charles Jayne, Samuel Chackalamannil, et al.
Bioorganic & Medicinal Chemistry Letters|June 24, 2021
SAR towards indoline and 3-azaindoline classes of IDO1 inhibitorsWensheng Yu, Yongqi Deng, Brett Hopkins, et al.
Journal of Medicinal Chemistry|April 9, 2026
From KRAS<sup><i>G12D</i></sup> to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug DesignXiaoshen Ma, David L Sloman, Timothy J Henderson, et al.
ACS Medicinal Chemistry Letters|January 29, 2016
Discovery of MK-8831, A Novel Spiro-Proline Macrocycle as a Pan-Genotypic HCV-NS3/4a Protease InhibitorSanthosh F Neelamkavil, Sony Agrawal, Thomas Bara, et al.
Journal of Medicinal Chemistry|March 3, 2022
Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral DosingDerun Li, David L Sloman, Abdelghani Achab, et al.
ACS Medicinal Chemistry Letters|August 16, 2023
Discovery of MK-8768, a Potent and Selective mGluR2 Negative Allosteric ModulatorMichael T Rudd, Peter J Manley, Barbara Hanney, et al.
ACS Medicinal Chemistry Letters|March 19, 2021
Carbamate and <i>N</i>-Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design of Tetrahydroquinoline IDO1 InhibitorsDerun Li, Yongqi Deng, Abdelghani Achab, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Journal of Medicinal Chemistry|June 26, 2024
Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRAS<sup>G12C</sup> InhibitorXiaoshen Ma, David L Sloman, Ruchia Duggal, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Novel Quinoline-Based P2-P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease InhibitorsUnmesh Shah, Charles Jayne, Samuel Chackalamannil, et al.
Bioorganic & Medicinal Chemistry Letters|June 24, 2021
SAR towards indoline and 3-azaindoline classes of IDO1 inhibitorsWensheng Yu, Yongqi Deng, Brett Hopkins, et al.
Journal of Medicinal Chemistry|April 9, 2026
From KRAS<sup><i>G12D</i></sup> to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug DesignXiaoshen Ma, David L Sloman, Timothy J Henderson, et al.
ACS Medicinal Chemistry Letters|January 29, 2016
Discovery of MK-8831, A Novel Spiro-Proline Macrocycle as a Pan-Genotypic HCV-NS3/4a Protease InhibitorSanthosh F Neelamkavil, Sony Agrawal, Thomas Bara, et al.
Journal of Medicinal Chemistry|March 3, 2022
Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral DosingDerun Li, David L Sloman, Abdelghani Achab, et al.
ACS Medicinal Chemistry Letters|August 16, 2023
Discovery of MK-8768, a Potent and Selective mGluR2 Negative Allosteric ModulatorMichael T Rudd, Peter J Manley, Barbara Hanney, et al.
ACS Medicinal Chemistry Letters|March 19, 2021
Carbamate and <i>N</i>-Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design of Tetrahydroquinoline IDO1 InhibitorsDerun Li, Yongqi Deng, Abdelghani Achab, et al.
Pageof 7